Mesenchymal stromal cells-based therapy in a murine model of elastase-induced emphysema: Simvastatin as a potential adjuvant in cellular homing

被引:1
作者
de Faria, Carolina Arruda [1 ]
Silva Junior, Wilson Araujo [1 ]
Coelho, Karoline Brito Caetano Andrade [2 ]
Bassi, Mirian [3 ]
Colombari, Eduardo [3 ]
Zanette, Dalila Luciola [4 ]
Ribeiro-Paes, Joao Tadeu [5 ]
机构
[1] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Genet, Ribeirao Preto, SP, Brazil
[2] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Cirurgia & Anat, Ribeirao Preto, SP, Brazil
[3] Univ Estadual Paulista Unesp, Fac Odontol, Dept Fisiol & Patol, Araraquara, SP, Brazil
[4] Fiocruz Parana, Inst Carlos Chagas, Lab Ciencias & Tecnol Aplicadas Saude, Curitiba, Parana, Brazil
[5] Univ Estadual Paulista, Univ Estadual Paulista, Dept Biotecnol, Sao Paulo, Brazil
关键词
Chronic obstructive pulmonary disease; COPD; Cell therapy; Mesenchymal stromal cells; MSC; Simvastatin; Cellular homing; Mouse; PLASMINOGEN-ACTIVATOR INHIBITOR-1; OBSTRUCTIVE PULMONARY-DISEASE; STEM-CELLS; PHASE-I; LUNG; IMPACT; INSULIN;
D O I
10.1016/j.pupt.2021.102075
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic Obstructive Pulmonary Disease - COPD is characterized by the destruction of alveolar walls associated to a chronic inflammatory response of the airways. There is no clinical therapy for COPD. In this context, cell-based therapies represent a promising therapeutic approach for chronic lung disease. The goal of this work was to evaluate the effect of simvastatin on cell-based therapy in a mice emphysema model. Female FVB mice received intranasal instillation of elastase (three consecutive doses of 50 ILL) in order to promote pulmonary emphysema. After 21 days of the first instillation, the animals were treated with Adipose-Derived Mesenchymal Stromal Cells (AD-MSC, 2.6 x 106) via retro-orbital infusion associated or not with simvastatin administrated daily via oral gavage (15 mg/kg/15d). Before and after these treatments, the histological and morphometrical analyses of the lung tissue, as so as lung function (whole body plethysmography) were evaluated. PAI-1 gene expression, an upregulated factor by ischemia that indicate a low survival of transplanted MSC, was also evaluated. The result regarding morphological and functional aspects of both lungs, presented no significant difference among the groups (AD-MSC or AD-MSC + Simvastatin). However, significant anatomical difference was observed in the right lung of the both groups of mice. The results shown a higher deposition of cells in the right lung, with might to be explained by anatomical differences (slightly higher right bronchi). Decreased levels of PAI-1 were observed in the simvastatin treated groups. The pulmonary ventilation was similar between the groups with only a tendency to a lower in the elastase treated animals due to a low respiratory frequency. In conclusion, the results suggest that both AD-MSC and simvastatin treatments could promote an improvement of morphological recovery of pulmonary emphysema, that it was more pronounced in the right lung.
引用
收藏
页数:10
相关论文
共 57 条
  • [1] [Anonymous], 2012, CURRENT CONCEPTS PRA
  • [2] Clinical applications of mesenchymal stem cells in chronic lung diseases
    Antoniou, Katerina M.
    Karagiannis, Konstantinos
    Tsitoura, Eliza
    Bibaki, Eleni
    Lasithiotaki, Ismini
    Proklou, Athanasia
    Spandidos, Demetrios A.
    Tzanakis, Nikos
    [J]. BIOMEDICAL REPORTS, 2018, 8 (04) : 314 - 318
  • [3] Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema
    Antunes, Mariana A.
    Abreu, Soraia C.
    Cruz, Fernanda F.
    Teixeira, Ana Clara
    Lopes-Pacheco, Migueias
    Bandeira, Elga
    Olsen, Priscilla C.
    Diaz, Bruno L.
    Takyia, Christina M.
    Freitas, Isalira P. R. G.
    Rocha, Nazareth N.
    Capelozzi, Vera L.
    Xisto, Debora G.
    Weiss, Daniel J.
    Morales, Marcelo M.
    Rocco, Patricia R. M.
    [J]. RESPIRATORY RESEARCH, 2014, 15
  • [4] MSC Based Therapies-New Perspectives for the Injured Lung
    Behnke, Judith
    Kremer, Sarah
    Shahzad, Tayyab
    Chao, Cho-Ming
    Boettcher-Friebertshaeuser, Eva
    Morty, Rory E.
    Bellusci, Saverio
    Ehrhardt, Harald
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (03)
  • [5] Mesenchymal stromal cells: a novel therapy for the treatment of chronic obstructive pulmonary disease?
    Broekman, Winifred
    Khedoe, Padmini P. S. J.
    Schepers, Koen
    Roelofs, Helene
    Stolk, Jan
    Hiemstra, Pieter S.
    [J]. THORAX, 2018, 73 (06) : 565 - 574
  • [6] Caramori Gaetano, 2012, Recenti Progressi in Medicina, V103, P31, DOI 10.1701/1022.11157
  • [7] Mesenchymal Stem Cell Administration in Patients with Chronic Obstructive Pulmonary Disease: State of the Science
    Cheng, Shih-Lung
    Lin, Ching-Hsiung
    Yao, Chao-Ling
    [J]. STEM CELLS INTERNATIONAL, 2017, 2017
  • [8] Hematopoietic and Mesenchymal Stem Cells for the Treatment of Chronic Respiratory Diseases: Role of Plasticity and Heterogeneity
    Conese, Massimo
    Piro, Donatella
    Carbone, Annalucia
    Castellani, Stefano
    Di Gioia, Sante
    [J]. SCIENTIFIC WORLD JOURNAL, 2014,
  • [9] Copland IB, 2007, BLOOD, V110, p61A
  • [10] Improved Autograft Survival of Mesenchymal Stromal Cells by Plasminogen Activator Inhibitor 1 Inhibition
    Copland, Ian B.
    Lord-Dufour, Simon
    Cuerquis, Jessica
    Coutu, Daniel L.
    Annabi, Borhane
    Wang, Eugenea
    Galipeau, Jacques
    [J]. STEM CELLS, 2009, 27 (02) : 467 - 477